AOD-9604 Research Hub

The C-terminal part of human growth hormone (hGH) is the source of the synthetic peptide counterpart AOD-9604. It was created as a short peptide fragment for use in experiments and matches amino acid residues 177–191 of the native 191-amino-acid growth hormone sequence. In contrast to full-length human growth hormone, AOD-9604 is a chemically synthesized peptide with a specific 15-amino acid sequence, making it a structurally unique research product for studying molecular signaling and peptide–receptor interactions.

The peptide originated from efforts to characterize the biological activity of individual regions of the growth hormone molecule. Early structure–function studies identified the C-terminal fragment as an area of interest, leading to the synthesis and subsequent investigation of AOD-9604 as an independent peptide analog. Since its initial characterization, it has been recognized in laboratory research for studies examining peptide pharmacology, receptor biology and intracellular signaling pathways associated with growth hormone-derived peptide fragments.

The synthetic peptide counterpart AOD-9604 is made up of the human growth hormone (hGH) C-terminal fragment, which corresponds to amino acid residues 177–191 of the genuine protein. A linear 15-amino acid sequence created via Solid Phase Peptide Synthesis (SPPS) makes up its main structure. AOD-9604 is a short peptide that lacks the parent hormone's entire structural architecture, in contrast to full-length human growth hormone, a 191-amino acid protein with a complicated tertiary structure.

Due to its relatively short sequence, AOD-9604 is not considered to adopt a stable secondary or tertiary structure in aqueous solution under physiological conditions. Instead, it exists predominantly as a flexible linear peptide, with any transient conformations influenced by environmental factors such as pH, ionic strength and solvent composition. The peptide exhibits good aqueous solubility in appropriate laboratory buffers and is routinely supplied as a lyophilized powder to maximize stability during storage and transport.

The amino acid composition of the AOD-9604 peptide determines its physicochemical characteristics, including its overall charge, hydrophilicity, and chromatographic behavior. The molecular stability relies heavily on proper handling and storage to minimize degradation by hydrolysis or proteolytic enzymes under laboratory conditions because it is a synthetic peptide analog that does not go through post-translational changes like glycosylation.

Current laboratory investigations have examined AOD-9604 as a synthetic peptide analogue corresponding to amino acid residues 177–191 of human growth hormone (hGH). Unlike full-length hGH, published experimental studies describe AOD-9604 as a peptide fragment that has been investigated independently to characterize the biological activity associated with the C-terminal region of the parent protein. Structure–function studies have focused on determining whether this peptide fragment demonstrates molecular interactions distinct from those of intact growth hormone.

In vitro models have explored the interaction of AOD-9604 with signaling pathways involved in cellular metabolism and peptide-mediated signal transduction. Experimental investigations have examined its influence on intracellular kinase activity, transcriptional regulation and enzyme-associated pathways using cultured cell systems and biochemical assays. Although these studies have identified molecular responses following peptide exposure, the precise receptor responsible for mediating these effects has not been conclusively established in the published literature.

Further investigation into whether AOD-9604 interacts directly with the classical growth hormone receptor (GHR) has been published. The peptide has often been described by structural and functional studies as lacking the receptor-binding domains necessary for classical growth hormone receptor activation, indicating that whatever molecular activity that has been detected may be caused by other processes. Therefore, the exact molecular target of AOD-9604 is still being researched.

Experimental studies have also characterized intracellular signaling events associated with peptide exposure, including investigations of mitogen-activated protein kinase (MAPK)-related pathways, AMP-activated protein kinase (AMPK)-associated signaling, and other phosphorylation-dependent regulatory networks. These pathways have been examined using biochemical assays, phosphoproteomic analyses, and molecular biology techniques to investigate changes in intracellular signaling under controlled laboratory conditions. However, the direct relationship between AOD-9604 and these signaling pathways has not been fully defined and continues to be investigated.

Current laboratory investigations, therefore, characterize AOD-9604 as an experimental peptide fragment whose molecular mechanism remains incompletely understood. Ongoing research continues to examine its receptor interactions, intracellular signaling pathways, and biochemical properties using cell-based assays, structural biology and preclinical experimental models to further define its mechanism of action.

AOD-9604 is a synthetic peptide analog that is typically manufactured using Solid Phase Peptide Synthesis (SPPS), a well-established technique for producing short peptide sequences with high precision and reproducibility. Following synthesis, the crude peptide undergoes purification, most commonly by preparative high-performance liquid chromatography (HPLC), to remove truncated peptide sequences, residual reagents and other synthesis-related impurities.

Whilst analytical high-performance liquid chromatography (HPLC) is typically employed to analyze peptide purity and assess batch-to-batch consistency, liquid chromatography–mass spectrometry (LC-MS) is applied to validate peptide identification and confirm the anticipated molecular mass of AOD-9604. Analytical methods such as peptide mapping or amino acid analysis may be used as needed to further characterize the finished product.

Before the peptide is made available for use in research, conventional quality assurance methods include identity confirmation, purity determination, and batch-specific quality testing. In order to provide traceable verification of manufacturing consistency for laboratory research applications, the resulting analytical data are recorded within a Certificate of Analysis (CoA), which usually contains the batch number, peptide identity, purity specification, molecular mass confirmation, and other pertinent quality control information.

AOD-9604 is typically supplied as a lyophilized peptide to maximize stability during storage and transport. The lyophilized material should be stored in accordance with the manufacturer’s recommendations, preferably under refrigerated conditions (2–8°C), and protected from moisture, excessive heat and direct light.

Prior to laboratory usage, the peptide should be handled according to established laboratory procedures and the manufacturer’s applicable product specifications and handled gently to minimize foaming and preserve peptide integrity.